BACKGROUND:Men and women respond differently to asthma. PATIENTS AND METHODS: Maximal inspiratory mouth pressure (P(Imax)), beta(2)-agonist consumption, and perception of dyspnea (POD) were measured in 22 women and 22 men with mild persistent-to-moderate asthma. Next, the women were randomized into two groups: those who received inspiratory muscle training and those who received sham training. The training ended when the P(Imax) of the training group was equal to that of the male subjects. POD was then measured once again. RESULTS: Baseline P(Imax) was significantly lower (p < 0.01) while POD and mean daily beta(2)-agonist consumption were significantly higher in the female subjects. P(Imax) reached the level of the male subjects at the end of the 20th week of training. The increase in the P(Imax) was associated with a statistically significant decrease in mean daily beta(2)-agonist use and in POD to a similar level as in male subjects. CONCLUSIONS:POD and mean daily beta(2)-agonist consumption in asthmatic women are significantly higher, and the P(Imax) significantly lower, than that of their male counterparts. When the P(Imax) of female subjects following training is equal to that in male subjects, the differences in POD and mean daily beta(2)-agonist consumption disappear.
RCT Entities:
BACKGROUND:Men and women respond differently to asthma. PATIENTS AND METHODS: Maximal inspiratory mouth pressure (P(Imax)), beta(2)-agonist consumption, and perception of dyspnea (POD) were measured in 22 women and 22 men with mild persistent-to-moderate asthma. Next, the women were randomized into two groups: those who received inspiratory muscle training and those who received sham training. The training ended when the P(Imax) of the training group was equal to that of the male subjects. POD was then measured once again. RESULTS: Baseline P(Imax) was significantly lower (p < 0.01) while POD and mean daily beta(2)-agonist consumption were significantly higher in the female subjects. P(Imax) reached the level of the male subjects at the end of the 20th week of training. The increase in the P(Imax) was associated with a statistically significant decrease in mean daily beta(2)-agonist use and in POD to a similar level as in male subjects. CONCLUSIONS: POD and mean daily beta(2)-agonist consumption in asthmatic women are significantly higher, and the P(Imax) significantly lower, than that of their male counterparts. When the P(Imax) of female subjects following training is equal to that in male subjects, the differences in POD and mean daily beta(2)-agonist consumption disappear.
Authors: Ivanizia S Silva; Guilherme A F Fregonezi; Fernando A L Dias; Cibele T D Ribeiro; Ricardo O Guerra; Gardenia M H Ferreira Journal: Cochrane Database Syst Rev Date: 2013-09-08
Authors: Jennifer A Kannan; David I Bernstein; Cheryl K Bernstein; Patrick H Ryan; Jonathan A Bernstein; Manuel S Villareal; Andrew M Smith; Peter H Lenz; Tolly G Epstein Journal: Ann Allergy Asthma Immunol Date: 2015-07-21 Impact factor: 6.347
Authors: Jennifer W McCallister; Janet T Holbrook; Christine Y Wei; Jonathan P Parsons; Cathy G Benninger; Anne E Dixon; Lynn B Gerald; John G Mastronarde Journal: Respir Med Date: 2013-08-21 Impact factor: 3.415
Authors: Axel C Carlsson; Per Wändell; Urban Ösby; Ramin Zarrinkoub; Björn Wettermark; Gunnar Ljunggren Journal: BMC Public Health Date: 2013-07-18 Impact factor: 3.295